National Medical Insurance Authority Supports Brain-Computer Interface and Other New Technologies Entering Clinical Practice

　　Glorion Hui July 31st | To support innovative development of pharmaceuticals and medical devices, the National Medical Insurance Authority has formulated a new pricing mechanism for new drugs entering the market, adding over 100 projects related to healthcare technology. The guidelines for neurosystem-specific items establish "brain-computer interface insertion fees" and "brain-computer interface adaptation fees", among others, allowing brain-computer interface technologies that have been approved for clinical use to quickly enter clinical practice and charge for their services. Similarly, the guidelines for otolaryngology-specific items establish "artificial eardrum implantation fees" and "speech device installation fees", encouraging hospitals to help more patients "hear and speak". The guidelines for radiation therapy-specific items establish prices for projects like "proton therapy" and "heavy ion therapy", promoting the clinical application of high-end medical equipment. Meanwhile, to encourage pharmaceutical research innovation, the National Medical Insurance Authority has also formulated a new pricing mechanism for new drugs entering the market.